By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lundbeck Inc. 

Four Parkway North
Suite 200
Deerfield  Illinois  60015  U.S.A.
Phone: 800-455-1141 Fax: 847-282-1001

Lundbeck Inc. - Making a Difference One Patient at a Time

Headquartered in Deerfield, Illinois, with a portfolio of 17 specialty therapies and a pipeline of promising central nervous system (CNS) drugs, Lundbeck Inc. is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available.

As a wholly-owned subsidiary of H. Lundbeck A/S of Denmark, Lundbeck Inc. has a unique ownership structure. The company is 70 percent owned by the Lundbeck Foundation, which contributes millions annually to scientific research. In 2009, the Foundation granted more than $58 million to support research in biomedical and natural sciences.

Lundbeck Inc. offers the chance to make a difference while working in a unique and innovative environment. We are united by our passion and responsibility for helping the people with unmet medical needs. In addition to our extensive CNS pipeline that addresses a range of disorders from Alzheimer’s disease to Parkinson’s disease and depression, Lundbeck focuses on rare diseases with five orphan-designated therapies on the market and one more in late-stage development.

Our team of 350 pharmaceutical professionals, including an experienced team of clinical, regulatory and commercial experts, has a proven track record of working effectively with the U.S. Food and Drug Administration, developing and marketing high-need drugs that improve patients’ lives, and quickly and cost effectively bringing new products to market. Our operational excellence, diverse commercial portfolio and compelling development pipeline puts us in an excellent position for continued innovation and growth that will benefit patients for years to come.

At Lundbeck you can make a difference one patient at a time. If you wish to join a team where the challenges are great, the mission is meaningful and you can directly see the results of your hard work, Lundbeck may be the place for you.

Key Statistics

Ownership: Public

Web Site: Lundbeck Inc.
Symbol: LUN.CO

Company News
Lundbeck Inc. (LUN.CO) Release: Analysis Of Responder Data From Clinical Trials Evaluating NORTHERA (Droxidopa) For The Treatment Of Symptomatic Neurogenic Orthostatic Hypotension 6/16/2015 12:02:49 PM
Otsuka America Pharmaceutical, Inc. And Lundbeck Inc. (LUN.CO) To Present Data On Investigational Compound Brexpiprazole In Schizophrenia And Major Depressive Disorder At American Psychiatric Association Annual Meeting 5/13/2015 11:37:06 AM
Lundbeck Inc. (LUN.CO) Initiates Clinical Trial Evaluating Clobazam For Dravet Syndrome 3/17/2015 10:02:36 AM
Lundbeck Inc. (LUN.CO) CEO Ulf Wiinberg Resigns After Breach Of Company Rules 11/24/2014 7:07:42 AM
Lundbeck Inc. (LUN.CO) Partners With The Hereditary Disease Foundation, Pledges Five Additional Years Of Support For Build Hope For Huntington’s Disease Campaign 11/6/2014 11:12:26 AM
Lundbeck Inc. (LUN.CO) Provides Update On New Drug Application For Intravenous Carbamazepine 10/27/2014 11:01:51 AM
U.S. FDA Accepts Otsuka Pharmaceutical Co., Ltd. And Lundbeck Inc. (LUN.CO)'s Filing For Review Of Brexpiprazole For The Treatment Of Schizophrenia And As Adjunctive Therapy For The Treatment Of Major Depression 9/24/2014 10:33:08 AM
Lundbeck Inc. (LUN.CO) Announces Availability Of NORTHERA™ (droxidopa) Capsules In The U.S. For Symptomatic Neurogenic Orthostatic Hypotension 9/2/2014 11:02:33 AM
Lundbeck Inc. (LUN.CO) Successfully Completes Tender Offer For Chelsea Therapeutics, Inc. (CHTP) 6/23/2014 7:24:13 AM
Lundbeck Inc. (LUN.CO) Part Of Major Advances In The Understanding Of Parkinson's Disease 5/15/2014 12:12:22 PM